Core Insights - Clarivate Plc has announced a multi-year partnership with the Canadian Research Knowledge Network (CRKN) to provide expanded access to the Web of Science for 55 Canadian universities, enhancing research collaborations and accessibility [1][4]. Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [5]. Industry Impact - The partnership aims to support Canadian researchers by providing access to the Web of Science API, which includes rich metadata to aid research projects, as well as access to the Derwent Innovations Index and the Policy Citation Index to understand the societal impact of research outputs [3][4]. - Canada is recognized for its collaborative position in global academic research, with contributions in innovation and patents exceeding the international average [4].

Core Viewpoint - Clarivate Plc has successfully completed an incremental upsize of its term loan B credit facility, taking advantage of improved credit market conditions to extend the maturity of its 2026 debt [1][3]. Financial Summary - The company incurred a new $500 million tranche of incremental term loans maturing in 2031, with an interest rate margin of 325 basis points per annum, and these loans will not be subject to amortization [2]. - The proceeds from the new term loans were used to redeem $500 million of the outstanding 4.50% senior secured notes due 2026, leaving $200 million of the notes remaining outstanding after the partial redemption [2]. Management Commentary - The Executive Vice President and Chief Financial Officer of the company expressed satisfaction with the ability to extend the majority of the 2026 debt maturity, highlighting the company's strong cash flow and flexibility in capital allocation moving forward [3].

Core Insights - Clarivate Plc has renewed its partnership with CAPES, significantly expanding access to academic and life sciences data across over 400 Brazilian institutions, increasing institutional coverage by 57% compared to the previous contract [1][2][6] - The partnership aims to democratize access to critical scientific information, enabling researchers and practitioners to conduct innovative research and improve patient care [3][4][6] - The agreement enhances access to various research tools, including Web of Science, Journal Citation Reports, and Cortellis Drug Discovery Intelligence, supporting evidence-based discovery and decision-making [2][5][6] Company and Industry Impact - The collaboration with CAPES reflects a commitment to advancing scientific excellence and reducing regional disparities in Brazil's research landscape [4][6] - The expanded access to trusted research tools is expected to strengthen postgraduate programs and elevate the global visibility of Brazilian research [6][7] - Brazil's research output shows a strong focus on Sustainable Development Goals, particularly in Life Sciences and Medicine, with a notable emphasis on international collaboration [10]

Core Insights - Clarivate Plc has launched RiskMark, an AI-powered solution designed to help trademark professionals evaluate trademark risk and generate evidence-backed arguments efficiently [1][4] - RiskMark utilizes a vast database of 172.5 million trademark records and over 5 million global court and administrative records to assess similarity risk [2] - The solution employs generative and predictive AI to provide near-instant results on various aspects of trademark evaluation, enhancing decision-making speed and confidence [2] Company Overview - Clarivate is recognized as a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services across multiple sectors including Intellectual Property [5] - The company aims to empower IP professionals with trustworthy AI-driven insights to assess risk and streamline the drafting process for trademark-related arguments [4]

Q1 2021 Earnings Supplemental Materials April 29, 2021 Forward-Looking Statements These materials contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, outlook, anticipated cost savings, anticipa ...

Transaction Overview - Clarivate will acquire ProQuest for $5.3 billion [9], including refinancing approximately $1.0 billion of ProQuest's net debt [9] - ProQuest shareholders will receive approximately $1.3 billion of Clarivate shares, representing about 7% combined ownership, and approximately $3.0 billion in cash [9] - The transaction is expected to close in Q3 2021 [9] Financial Highlights (Combined Business) - The combined adjusted revenue for 2020 is approximately $2.6 billion [6, 10] - The combined adjusted EBITDA for 2020 is approximately $1.2 billion [10] with adjusted EBITDA margins of approximately 45% [10] - The combined adjusted EBITDA less CapEx for 2020 is approximately $1.0 billion [10] - Clarivate anticipates double-digit adjusted diluted EPS accretion in 2022 and mid-teens accretion in 2023 [6, 10, 40] Synergies and Cost Savings - The acquisition is expected to generate more than $100 million in run-rate cost savings [9, 10, 36, 44] and $10 million in CapEx synergies [10, 36] - These cost savings are expected to be fully realized within 15-18 months [10, 39, 44] ProQuest Overview - ProQuest has access to >5 million Dissertations [15], 20 million pages of newspapers [15], >6 Billion Digital Pages [15], 285 million Journal Articles [15], Data on 40 million Books [15], > 450,000 eBooks [15] - ProQuest's 2020 revenue was $876 million [22] with a 4% organic growth rate [22] - ProQuest's adjusted EBITDA was $253 million [22] with a 30% margin [22]

Financial Performance & Guidance - In 2020, Clarivate's Adjusted Revenue was $1.3 billion, Adjusted EBITDA was $487 million, Adjusted EBITDA Margin was 38%, and Adjusted Free Cash Flow was $264 million[16] - The company's 2021 guidance projects Adjusted Revenue between $1.8 billion and $1.84 billion, Adjusted EBITDA between $795 million and $825 million, an Adjusted EBITDA Margin between 44% and 45%, and Adjusted Free Cash Flow between $450 million and $500 million[18,68] - The company is targeting a near-term Adjusted EBITDA margin of 47%-48% and a medium-term goal of 50%[174] Growth Strategy & Market Opportunity - Clarivate addresses a total addressable market (TAM) exceeding $100 billion across four customer segments[58,109] - The company estimates a potential revenue opportunity of over $1 billion through account retention, up/cross-sell, and new logos across its customer segments[118] - The Life Sciences and Healthcare client case study shows revenue growth from $1.4 million in 2017 to $4.9 million in 2021, with 81% organic growth and a 38% CAGR[113] - The Academic and Government client case study shows revenue growth from $1.7 million in 2017 to $3.6 million in 2021, with 58% organic growth and a 23% CAGR[115] Operational Efficiency & Cost Savings - Clarivate achieved run-rate savings of $235 million exiting 2021 through operational improvements, facilities rationalization, and digital transformation[61,171] - The Connected Workplace strategy resulted in $27 million in cost savings[80] Customer Focus & Engagement - Inside Sales significantly scaled this year with 24,000 accounts in Centers of Excellence, representing $375 million via continued investment in sales capacity[75] - The company aims to improve ease of doing business, with a goal to increase the score from 77 to 80 in the Customer Delight survey[90]

Core Insights - The Trademark filing trends 2025 report by Clarivate highlights the leading trademark filing jurisdictions and the largest trademark portfolios globally [1][2][3] Group 1: Trademark Filing Trends - Mainland China leads global trademark filings with 6.76 million applications in 2024, despite a three-year decline in activity [2][5] - The U.S. ranks second with 566,938 applications, while India is close behind with over 537,000 applications and a 10% average yearly growth over the last decade [2][5] - France, Mainland China, and Japan have experienced a consistent decline in trademark filing activity for three consecutive years, ending 2024 with the lowest filing volumes since 2017 [5] Group 2: Major Portfolio Owners - Seven brands consistently appear in the top 20 largest trademark portfolio lists, including Procter & Gamble, Nestlé, Apple, L'Oréal, Novartis, LG Electronics, and Unilever, each being among the largest portfolio owners in at least seven of the ten analyzed registers [1][5] - Australia has recovered to its 2021 trademark filing volume, primarily due to a 24% increase in applications by foreign-based brand owners in 2024 [5] Group 3: Strategic Insights - Gordon Samson from Clarivate emphasizes the importance for trademark attorneys to understand macro-trends and the economic interplay between jurisdictions to better manage intellectual property [3] - Integrating insights from the report into trademark and business strategies can help brands mitigate risks and capitalize on emerging opportunities [3]

Core Insights - Clarivate Plc has introduced Pathway Maps in its OFF-X platform, enhancing translational safety intelligence in drug development [1][3] - Over 30% of drug development failures are linked to safety issues, necessitating earlier identification of potential liabilities [1][2] - The integration of visual disease biology with comprehensive safety data allows researchers to make faster, more informed decisions [2][3] Company Overview - Clarivate is a global provider of transformative intelligence, offering data, insights, analytics, and workflow solutions across various sectors including Life Sciences & Healthcare [5] - The company aims to empower researchers with tools that streamline workflows and provide actionable insights to improve patient outcomes [3][5] Product Features - OFF-X supports researchers throughout the drug development lifecycle, from early discovery to post-marketing surveillance [4] - The platform combines proprietary physiological and disease pathway visualizations with curated safety data, enhancing risk evaluation [3][4] - The addition of Pathway Maps allows for disease-specific visualizations of key signaling pathways, facilitating quicker identification of safety liabilities [2][3]

Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025. Registration No. 333-286799 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jay Taragin c/o Churchill Capital Corp X 640 Fifth Avenue, 14th Floor New York, NY 10019 Telephone: (212) 380-7500 (Name, Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service) Copies to: Douglas S. Ell ...